AUTHOR=Hu Yani , Miao Pu , Chen Shunan , Mao Fengqian , Wang Suhong , Feng Jianhua , Chen Jie , Yu Lingyan , Dai Haibin 

TITLE=Cost-effectiveness of therapeutic drug monitoring of perampanel for pediatrics with epilepsy: real-world data

JOURNAL=Frontiers in Pharmacology

VOLUME=Volume 16 - 2025

YEAR=2025

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1549069

DOI=10.3389/fphar.2025.1549069

ISSN=1663-9812

ABSTRACT=AimsIncreased plasma concentration of perampanel (PER) is associated with reduction in seizure frequency. It is unclear how much better therapeutic drug monitoring (TDM) is than without TDM in pediatric using PER. This study aims to estimate the effectiveness and cost-effectiveness of TDM of PER in children with epilepsy.MethodsAn observational study was conducted to compare clinical and economic outcomes between the TDM and non-TDM groups. We used a Markov model to evaluate the cost-effectiveness of TDM from a healthcare system perspective based on data from an observation cohort study that included four health states. High cost-effectiveness thresholds were defined as < $12,814. One-way, probabilistic sensitivity analyses and scenario analyses were conducted to explore uncertainty.ResultsTDM of the PER improved the 1-year seizure-free rate from 16.7% to 48.1% and the >50% reduction in seizure frequency from 58.3% to 83.3% in children with epilepsy (P = 0.035). The TDM of the PER is highly cost-effective, with an ICER of $732.90 per QALY gained (79.11% probability of being highly cost-effective). TDM was dominant, with an increased QALY of 0.86 and a decreased cost of $1,586.07 in children with newly diagnosed epilepsy. The number of days of hospitalization in the no response state, which is related to the cost of hospitalization, is the largest influencing factor.ConclusionTDM of PER could reduce the seizure frequency and is cost-effective for children with epilepsy. TDM of the PER in newly diagnosed epilepsy patients is strongly dominant because of its improvement in efficacy and reduction in cost.